Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared on X:
“Sara Tolaney presents the practice-changing results from ASCENT-04.
Among patients with PDL1+ mTNBC, first-line SG/pembrolizumab improved PFS vs chemo/pembrolizumab (11.2 vs 7.8 months, HR 0.65, p<0.001). Positive OS trend, despite built in crossover.
Huge news for a major unmet need in breast oncology!”
You can find more posts featuring Paolo Tarantino on OncoDaily.